Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents

Journal of Clinical Oncology

Volumn 26, Issue 8, 2008, Pages 1324-1330

  Pond, Gregory R ^a   Siu, Lillian L ^a   Moore, Malcolm ^a   Oza, Amit ^a   Hirte, Hal W ^a   Winquist, Eric ^a   Goss, Glenwood ^a   Hudes, Gary ^a   Townsley, Carol A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; 7 HYDROXYSTAUROSPORINE; ALBUMIN; BORTEZOMIB; CEDIRANIB; CISPLATIN; CREATININE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; GTI 2040; IMATINIB; ISPINESIB; LACTATE DEHYDROGENASE; LAPATINIB; OBLIMERSEN; PERIFOSINE; SORAFENIB; TEMSIROLIMUS; TIPIFARNIB; TOPOTECAN; VORINOSTAT; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG TARGETING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NOMOGRAM; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL MODEL; UNSPECIFIED SIDE EFFECT; DRUG TOXICITY; MIDDLE AGED; NEOPLASM; OUTCOME ASSESSMENT; PREDICTION AND FORECASTING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NOMOGRAMS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS;

EID: 41649121297     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.0673     Document Type: Article

References (10)

1. Agulnik M, Oza AM, Pond GR, et al: Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol 24:4801-4807, 2006
2. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005
3. Parulekar WR, Eisenhauer EA: Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: Theory and practice. J Natl Cancer Inst 96:990-997, 2004
4. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
5. Rogatko A, Babb JS, Wang H, et al: Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials. Clin Cancer Res 10:4645-4651, 2004
6. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
7. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
8. Liang KY, Zeger SL: Regression analysis for correlated data. Annu Rev Public Health 14:43-68, 1993
9. Kattan MW: Validating a prognostic model. Cancer 107:2523-2524, 2006
10. Efron B, Tibshirani, RJ: An Introduction to the Bootstrap. London, United Kingdom, Chapman and Hall, 1994